VARIQUEL

This brand name is authorized in Ireland, Malta, New Zealand, United Kingdom

Active ingredients

The drug VARIQUEL contains one active pharmaceutical ingredient (API):

1 Terlipressin UNII 4U092XZF0K - TERLIPRESSIN ACETATE

Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices. Read about Terlipressin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VARIQUEL Solution for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H01BA04	Terlipressin	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01B Posterior pituitary lobe hormones → H01BA Vasopressin and analogues
Discover more medicines within H01BA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 176347, 240964
Country: MT	Medicines Authority	Identifier(s): AA565/28402
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 21323